[Intolerance reactions to ionic and nonionic contrast media in cardiac diagnosis. A randomized double-blind study].
Reactions to an ionic and a nonionic contrast medium were compared in a randomized double-blind trial involving 1153 patients (897 men, 256 women; mean age 56 [18-84] years) who underwent left-heart catheterization with coronary angiography. 584 patients (group 1) received the ionic contrast medium meglumine diatrizoate (Urografin 76%), while 569 (group 2) received the nonionic iopromide (Ultravist -370). Reactions of skin and mucosae, heart and circulation, lungs and respiratory tract, as well as of the central nervous system were noted. There was no significant difference between the two groups with respect to age, weight, height, allergic predisposition, left-ventricular ejection fraction, or serum electrolyte concentrations. Mild reactions, not requiring any treatment, occurred in 108 of the 1153 patients (9.4%), 85 (14.6%) in group 1 and 23 (4%) in group 2 (P less than 0.001). Severe reaction requiring treatment occurred in eight patients of group 1 (1.4%) and 14 of group 2 (2.5%)--difference not significant. Ventricular fibrillation was more frequent among group 2 patients (four compared with one in group 1), while two of three asystoles requiring treatment occurred in group 1 patients. The results show that, while mild reactions not requiring treatment were clearly less frequent after nonionic contrast medium injection, the risk of severe reactions was not reduced by their use.
Machraoui
A
A
Abteilung für Kardiologie und Angiologie, Berufsgenossenschaftliche Krankenanstalten Bergmannsheil Bochum.
Hinrichsen
M
M
Jäger
D
D
Lemke
B
B
Drews
S
S
Lange
S
S
Barmeyer
J
J
D000293:Adolescent; D000328:Adult; D006328:Cardiac Catheterization; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000503:physiopathology; D003287:Contrast Media / Q000009:adverse effects*; D003974:Diatrizoate Meglumine / Q000009:adverse effects; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D007472:Iohexol / Q000009:adverse effects / Q000031:analogs & derivatives; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011859:Radiography
D003287:Contrast Media; D003974:Diatrizoate Meglumine; D007472:Iohexol; C038192:iopromide